MTOR and lymphangioma: Activation of the PI3K/AKT/mTOR and MEK/ERK pathways is further supported by higher expression of phospho-4E-BP1 and phospho-ERK, which are downstream of mTOR and MEK, respectively, in LECs of LM patients.